These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

778 related items for PubMed ID: 29887418

  • 1. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.
    Al Yami MS, Alfayez OM, Alsheikh R.
    Heart Lung Circ; 2018 Nov; 27(11):1301-1309. PubMed ID: 29887418
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
    Qin J, Song L.
    BMC Endocr Disord; 2022 May 12; 22(1):125. PubMed ID: 35546664
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V, Nicolucci A, Johnson DW, Tonelli M, Rossi MC, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque LI, Lloyd A, Ahmad N, Liu Y, Tiv S, Millard T, Gagliardi L, Kolanu N, Barmanray RD, McMorrow R, Raygoza Cortez AK, White H, Chen X, Zhou X, Liu J, Rodríguez AF, González-Colmenero AD, Wang Y, Li L, Sutanto S, Solis RC, Díaz González-Colmenero F, Rodriguez-Gutierrez R, Walsh M, Guyatt G, Strippoli GFM.
    BMJ; 2021 Jan 13; 372():m4573. PubMed ID: 33441402
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H, Zaccardi F, Khunti K, Seidu S, Davies MJ, Gray LJ.
    Diabet Med; 2019 Apr 13; 36(4):444-452. PubMed ID: 30653708
    [Abstract] [Full Text] [Related]

  • 10. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
    Lin DS, Lee JK, Hung CS, Chen WJ.
    Diabetologia; 2021 Dec 13; 64(12):2676-2686. PubMed ID: 34536085
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.
    Mannucci E, Dicembrini I, Nreu B, Monami M.
    Diabetes Obes Metab; 2020 Feb 13; 22(2):203-211. PubMed ID: 31595657
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y, Rosenblit PD.
    Curr Cardiol Rep; 2018 Sep 26; 20(11):113. PubMed ID: 30259238
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta-Analysis of Randomized-Controlled Trials.
    Hosseinpour A, Sood A, Kamalpour J, Zandi E, Pakmehr S, Hosseinpour H, Sood A, Agrawal A, Gupta R.
    Clin Cardiol; 2024 Jul 26; 47(7):e24314. PubMed ID: 38953365
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Usefulness of Glucagon-Like Peptide-1 Receptor Agonists to Reduce Adverse Cardiovascular Disease Events in Patients with Type 2 Diabetes Mellitus.
    Grewal S, Zaman N, Borgatta L, Nudy M, Foy AJ, Peterson B.
    Am J Cardiol; 2021 Sep 01; 154():48-53. PubMed ID: 34266665
    [Abstract] [Full Text] [Related]

  • 20. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.
    Wroge J, Williams NT.
    Ann Pharmacother; 2016 Dec 01; 50(12):1041-1050. PubMed ID: 27531946
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.